Page not found

The page you are trying to reach is unavailable or it may no longer exist.

To find what you are looking for, please click on any of the links in the site map:

Privacy
Contact us
Summary of Product Characteristics
Safety information

Disclaimer: This is an international website for Tyverb^® (lapatinib) and is intended for Healthcare Professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

9/20 G-TYV-1236420 © 2020 Novartis AG | Use of this website is subject to our Terms of Use | Cookie Settings

Disclaimer

The link you have chosen leads to a site maintained by a third party over whom Novartis has no control. As such, Novartis makes no representation as to the accuracy or any other aspect of the information on this site.

The clinical use in these resources may not be consistent with the approved indications for Tyverb. The information in these resources is not country-specific and may contain information that is outside the approved indications where you practice. Please contact your local Novartis representative for the latest product information specific to your country.

This is an international site for Tyverb^® (lapatinib) and is intended for Healthcare Professionals outside the US.

TYVERB^® (lapatinib) is approved in three indications in multiple countries around the world. 60 countries

Healthcare Professionals
Patients

Choose Country

Germany United States